Ronald N. Marcus, MD

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

March 24, 2025

Xanomeline and trospium showed improvement in agitation as measured by the PANSS-Excited Component in participants with acute exacerbations of schizophrenia.

Paul P. Yeung , Alan Breier , Haiyuan Zhu , et al

Original Research

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

January 15, 2014

Robert L. Findling , Raymond Mankoski , Karen Timko , et al

Article

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

July 26, 2011

Ronald N. Marcus , Randall Owen , George Manos , et al

Original Research

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

December 17, 2009

J. Craig Nelson , Michael E. Thase , Madhukar H. Trivedi , et al

Original Research

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

December 31, 2008

Madhukar H. Trivedi , Michael E. Thase , Maurizio Fava , et al

Original Research

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

December 15, 2008

Michael E. Thase , Madhukar H. Trivedi , J. Craig Nelson , et al

Original Research

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

December 2, 2008

Philip G. Janicak , Ira D. Glick , Stephen R. Marder , et al

Original Research

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

July 31, 2008

John W. Newcomer , Joao Alberto Campos , Ronald N. Marcus , et al

Letter to the Editor

Reply to Aripiprazole and Perphenazine: No Difference

November 15, 2007

John M. Kane , Herbert Y. Meltzer , William H. Carson, Jr. , et al

Original Research

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

October 15, 2007

Gilbert J. L'Italien , Daniel E. Casey , Hong J. Kan , et al

Original Research

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

October 15, 2007

Paul E. Keck, Jr. , Joseph R. Calabrese , Roger S. McIntyre , et al

Original Research

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

September 17, 2007

Gary S. Sachs , Bruce D. Gaulin , Rolando Gutierrez-Esteinou , et al

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

Reply to Aripiprazole and Perphenazine: No Difference

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

ELSEWHERE:

FOLLOW US:

Ronald N. Marcus, MD

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

Reply to Aripiprazole and Perphenazine: No Difference

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles